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ABSTRACT
The activation status of a set of pro-oncogenic tyrosine kinases in ovarian cancer 
patient samples was analyzed to define potential therapeutic targets. Frequent 
activation of HER family receptor tyrosine kinases, especially HER2, was observed. 
Studies in ovarian cancer cell lines confirmed the activation of HER2. Moreover, 
knockdown of HER2 caused a strong inhibition of their proliferation. Analyses of 
the action of agents that target HER2 indicated that the antibody drug conjugate 
trastuzumab-emtansine (T-DM1) caused a substantial antitumoral effect in vivo 
and in vitro, and potentiated the action of drugs used in the therapy of ovarian 
cancer. T-DM1 provoked cell cycle arrest in mitosis, and caused the appearance of 
aberrant mitotic spindles in cells treated with the drug. Biochemical experiments 
confirmed accumulation of the mitotic markers phospho-Histone H3 and phospho-
BUBR1 in cells treated with the drug. Prolonged treatment of ovarian cancer cells 
with T-DM1 provoked the appearance of multinucleated cells which later led to cell 
death. Together, these data indicate that HER2 represents an important oncogene 
in ovarian cancer, and suggest that targeting this tyrosine kinase with T-DM1 may 
be therapeutically effective, especially in ovarian tumors with high content of HER2.
INTRODUCTION
Ovarian cancer represents the leading cause of 
death from gynecological malignancies in western 
countries [1]. The yearly estimated incidence is of 
12 new cases for every 100,000 women and a death 
rate of 8 women for every 100,000 women. Although 
advances in surgical and chemotherapeutic treatments 
have resulted in improvements in outcome, metastatic 
ovarian cancer is still incurable mainly due to the lack 
of effective therapeutic strategies [1, 2]. Because of this, 
intense efforts are being carried out to define potential 
molecular targets that may augment survival of patients 
with ovarian cancer. In this respect, several reports have 
identified potential therapeutic targets and the efficacy 
of treatments against such targets is being analyzed 
in clinical trials in various phases of development [1]. 
Among such experimental treatments, agents acting on 
tyrosine kinases have received special attention. Thus, 
agents targeting vascular endothelial growth factor 
(VEGF) signaling have shown efficacy in preclinical 
models when combined to chemotherapy [3, 4]. Moreover, 
based on positive results obtained in clinical trials using 
bevacizumab-based combinations [5, 6], on November 14, 
2014, the Food and Drug Administration (FDA) approved 
bevacizumab in combination with chemotherapy for the 
treatment of patients with platinum-resistant recurrent 
epithelial ovarian cancer. The platelet-derived growth 
factor receptors (PDGFR) and their ligands [7], and c-Kit 
[8] are overexpressed in ovarian cancers. However, Phase 
II trials have reported negative results in patients treated 
with imatinib, which targets both PDGFR and c-Kit [1].
Several reports indicate that the ErbB/HER family 
of receptor tyrosine kinases may represent alternative 
targets in ovarian cancer [1]. In fact, the epidermal growth 
factor receptor (EGFR) is expressed in 70% of ovarian 
tumors [9] and agents that target this receptor have shown 
antitumor activity in preclinical models [10]. However, 
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clinical results using EGFR-targeted agents have indicated 
that such agents offer limited benefit [1]. Expression of 
the related ErbB2/HER2 transmembrane tyrosine kinase 
has been reported in ovarian cancer [11]. The success of 
therapies against this receptor in other tumoral pathologies, 
especially in breast cancer [12], led to the development of 
clinical studies aimed at the evaluation of the efficacy of 
such therapies in HER2 positive ovarian tumors. A phase 
II trial on the efficacy of trastuzumab, an antibody against 
HER2, in ovarian cancer patients indicated that 7% of 
treated patients responded to this agent, with 39% of 
the patients showing stabilization of the disease [13]. 
Pertuzumab, another anti-HER2 antibody which acts by 
preventing dimerization of HER2 with other HER family 
receptors, has been reported to augment the antitumoral 
properties of gemcitabine [14]. Interestingly, preclinical 
studies have shown that combination of trastuzumab and 
pertuzumab may be more efficacious than treatment with 
single antibodies [15]. In an RNAi-based study, Sheng and 
colleagues identified another HER family receptor, HER3, 
as a potential target in ovarian cancer [16]. RNAi against 
this receptor reduced ovarian cancer cell growth in vitro 
and an antibody against HER3 reduced tumor growth in 
mice xenografted with human ovarian cancer cells. More 
recently, HER3 has been reported to be a relevant player 
implicated in the facilitation of hematogenous spread of 
ovarian cancer [17].
Because of the relevance of tyrosine kinases in 
cancer, a study to evaluate the expression of several of 
these kinases in ovarian cancer was carried out. From the 
whole tyrosine kinase kinome, and with the purpose of 
identifying targets amenable for therapeutic intervention, we 
selected 22 tyrosine kinases against which drugs are already 
approved for clinical use or in advanced stages of clinical 
development. Using patient-derived tumoral samples, we 
observed that HER2 was active in most of the samples 
analyzed. We show that a trastuzumab-drug conjugate 
outweighed the antitumoral efficacy of other drugs currently 
used for the targeting of HER2, including trastuzumab or 
pertuzumab, or the small molecule HER2 inhibitor lapatinib.
RESULTS
Active tyrosine kinase profiling in ovarian cancer
Given the relevance of tyrosine kinases in cancer 
initiation/progression, we designed a study to evaluate 
the activation status of several tyrosine kinases in ovarian 
cancer. We decided to study activation status rather than 
expression levels, since a more accurate evaluation of 
their potential relevance in cancer initiation/progression 
is the analysis of their functionality, which is linked to 
their activation status [18]. The latter can be analyzed by 
direct activity measurements, but is more often assessed 
by evaluation of tyrosine phosphorylation of residues 
which are used as readouts of the activation status of the 
tyrosine kinase. Another prerequisite of the study design 
was to analyze tyrosine kinases against which drugs were 
already approved or under clinical evaluation, with the aim 
of rapidly translating the observed findings to the clinical 
setting. This restricted the analyses to 22 tyrosine kinases 
including receptor and cytosolic tyrosine kinases. The list 
of the kinases selected and drugs that act on them is shown 
in Table 1. Another three receptor tyrosine kinases, HER4, 
Dtk and EphA2, were also added to the study. The kinase 
HER4 was included because of the relevant role of HER 
receptors in cancer, even though agents against this kinase 
are not under clinical development. Two other kinases, 
Dtk and EphA2, were also included in the array. They 
were expected to be inactive and act as negative controls.
Sixteen ovarian cancer tumors, whose patient 
characteristics are shown in Table 2, were analyzed 
by antibody arrays. Because of the lack of available 
commercial arrays covering all the desired tyrosine 
kinases we prepared the antibody arrays in house, after 
carefully testing different antibodies against each antigen 
to select the capture antibodies to be used in the blots. 
Duplicate spots of each antibody were adsorbed onto a 
nitrocellulose membrane, and protein lysates from the 
different ovarian tumor samples hybridized to the antibody 
arrays. Figure 1A describes a map with the position of the 
different capture antibodies in the array and Figure 1B 
shows data representative from an array obtained upon 
incubation of an ovarian tumor protein lysate. Figure 1C 
shows that the most frequently activated tyrosine kinases 
in ovarian cancer samples were HER2 (95% of patients), 
HER3 (80%), EGFR (37%), FAK (37%) and HER4 
(25%). Of note, these analyses also revealed the frequent 
coexistence of several activated kinases in a single tumor 
(Figure 1D).
HER2 knockdown restricts the proliferation of 
ovarian cancer cells
The above studies indicated that HER receptors, 
particularly HER2, were constitutively active in a large 
proportion of ovarian cancer samples. To investigate the 
relevance of these receptors in ovarian cancer proliferation, 
we used four ovarian carcinoma cell lines on which 
the activation status of HER receptors was analyzed by 
immunoblotting. The cell lines SKOV3 and OVCAR8 
expressed active forms of EGFR, HER2 and HER3 
(Figure 2A), and expression of such activated forms was not 
substantially affected by the presence of serum in the media. 
IGROV1 cells showed expression and activation of EGFR, 
HER2 and HER4 receptors. The cell lines A2780 and 
IGROV1 expressed very small amounts of active HER2 as 
compared to the other cell lines (Figure 2A). A2780 did not 
express detectable levels of active EGFR. Of note, HER2 
was the only HER family receptor expressed and activated 
in all four ovarian cancer cell lines (Figure 2A and 2B). This 
last observation falls in line with the data obtained in patient 
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Table 1: Tyrosine kinases analyzed and available drugs that act on them
Name Drugs
EGFR Gefitinib, Erlotinib Cetuximab, Lapatinib, Afatinib, Neratinib
HER2 Trastuzumab, Lapatinib, Pertuzumab, T-DM1, Afatinib, Neratinib
HER3 Sapitinib, MM-121, Patritumab, Canertinib
c-Kit Imatinib, Nilotinib
Met Crizotinib, Cabozantinib, Foretinib
PDGFRα Imatinib, Ponatinib Sorafenib, Pazopanib
PDGFRβ Imatinib, Sunitinib, Axitinib Sorafenib, Pazopanib
Flt3 Quizartinib, Sunitinib, Lestaurtinib
CSF-1R Lucitanib
Ret1 Cabozantinib, Vandetanib, Regorafenib, Ponatinib, Sunitinib
Ret2 Cabozantinib, Vandetanib, Regorafenib, Ponatinib, Sunitinib
IGF1R Figitumumab, Ganitumab, Cixutumumab, Dalotuzumab, Robatumumab
VGFR1 Pazopanib, Sunitinib, Vatalanib
VGFR2 Ramucirumab, Pazopanib, Sunitinib, Vandetanib, Regorafenib, Lenvatinib
VGFR3 Pazopanib, Lenvatinib, Cediranib
FAK Defactinib, GSK-2256098, PF-562,27, VS-4718
Src Dasatinib, Saracatinib, Bosutinib
Abl Imatinib, Nilotinib, Dasatinib, Ponatinib
FGFR1 Dovitinib, Lucitanib, BGJ398, AZD4547
FGFR2 Dovitinib, Lucitanib, BGJ398, AZD4547
FGFR3 Dovitinib, BGJ398, AZD4547
FGFR4 BGJ398, AZD4547
Table 2: Patient characteristics
Age Mean: 60.37 (43–77) % n = 16
Tumor type Cystoadenocarcinoma 68.75% n = 11
Tumor borderline 6.25% n = 1
Serous carcinoma 18.75% n = 3
Undifferentiated 6.25% n = 1
Stage IA 6.25% n = 1
IIIA 12.50% n = 2
IIB 12.50% n = 2
IIC 12.50% n = 2
IIIC 56.25% n = 9
ECOG 0 7.70% n = 1
1 61.50% n = 8
2 23.10% n = 3
4 7.70% n = 1
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samples using the antibody arrays, which indicated HER2 as 
the most frequently activated kinase.
To explore the relevance of HER2 in controlling 
the proliferation of ovarian cancer cells, we knocked 
down HER2 levels in the four ovarian cancer cell 
lines by the use of RNAi. From the five RNAi vectors 
analyzed, the two of them which caused a more 
important decrease in HER2 were used to carry out the 
functional studies. As shown in Figure 2C, knockdown 
of HER2 was efficiently obtained in the four cell lines 
by either of the two shRNAs used. Knockdown of 
HER2 profoundly affected proliferation of SKOV3 and 
OVCAR8 (Figure 2D). In contrast, little effect on cell 
proliferation was observed by knocking down HER2 in 
A2780 or IGROV1 cells.
Pharmacological targeting of HER2 in  
ovarian cancer
The antiproliferative effects observed using 
the genetic targeting of HER2 in ovarian cancer cells 
suggested that pharmacologically acting on this receptor 
could exert an antitumoral action in ovarian cancer. We 
therefore concentrated in evaluating the effect of highly 
specific drugs approved for the targeting of HER2. 
The four ovarian cancer cell lines were treated with 
trastuzumab, pertuzumab, lapatinib or the antibody-
drug conjugate trastuzumab-emtansine (T-DM1) [19]. 
Control or treated cell cultures were counted after 7 days 
of treatment. Addition of trastuzumab or pertuzumab did 
not affect the proliferation of the four ovarian cancer 
cell lines analyzed (Figure 3A). In contrast, a strong 
antiproliferative effect was observed in the case of T-DM1 
in all the cell lines explored. The most sensitive cell line to 
T-DM1 was the SKOV3, while the less sensitive resulted 
to be the A2780. In SKOV3 cells lapatinib slightly 
reduced proliferation, while in OVCAR8 and A2780 the 
effect of that drug was marginal. Interestingly, lapatinib 
substantially inhibited the proliferation of IGROV1 
cells, even though this cell line was quite insensitive to 
HER2 knockdown. Interestingly, these cells were also 
quite sensitive to the action of T-DM1. Dose response 
curves performed on the four ovarian cancer cell lines 
confirmed the high degree of sensitivity of SKOV3 cells 
to T-DM1 with respect to the other cell lines (Figure 3B). 
In fact, under these conditions, the IC50 value for the 
Figure 1: Expression of activated forms of different tyrosine kinases (TKs) in tumor samples from patients with ovarian 
cancer. A. 2D map detailing the positions of the different capture antibodies used. C+: positive controls. Ig or PBS: negative controls.  
B. Image from a representative array of an ovarian tumor sample. C. Frequency of activation of the different phospho-TKs analyzed in the 
array in the ovarian tumor samples. D. Phospho-TKs activated in each tumor are shown by black squares.
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antiproliferative effect of T-DM1 on SKOV3 cells was 
in the low picomolar range (IC50=20 pM), while for 
the rest of the ovarian cancer cell lines the IC50 values 
were > 10 nM.
T-DM1 is effective in vivo and potentiates the 
action of standard of care drugs
Part of the antitumoral effect of trastuzumab is due 
to antibody-dependent cellular toxicity immunological 
mechanisms [20]. Therefore, it is possible that its 
antitumoral action on ovarian cancer cells could be 
restricted in the in vitro conditions. Because of this, 
in vivo experiments comparing the antitumoral action 
of trastuzumab and T-DM1 were performed using mice 
injected with SKOV3 cells (Figure 3C). SKOV3 cells 
were selected for these studies because of its relatively 
high complement of HER2 receptors and their sensitivity 
to T-DM1 in vitro. These studies showed that trastuzumab 
slowed tumor growth in vivo when compared to the 
growth of tumors in untreated mice. However, the tumors 
continued to increase in size along time. In fact, no 
regressions of the tumors were observed in mice treated 
with trastuzumab. In this experimental setting T-DM1 not 
only prevented tumor growth but produced regression of 
the tumors. In fact, after two doses of T-DM1 the tumors 
in some mice were undetectable after 21 days from 
the initial injection of the drug. Moreover, no relapses 
were observed at the site of injection for up to 72 days 
after discontinuation of the treatments (Figure 3D). 
Biochemically, trastuzumab and T-DM1 did not affect 
the total level of HER2 in the tumors (Supplementary 
Figure 1). T-DM1 decreased the amount of pHER3 and 
pAKT to a higher extent than trastuzumab. Increased 
Figure 2: Relevance of HER2 in the proliferation of ovarian cancer cells. Activation A. and total levels B. of EGFR, HER2, 
HER3 and HER4 in four ovarian cancer cell lines cultured for 12 hours in the presence or absence of FBS. Activated forms of the HER 
receptors were analyzed by immunoprecipitation with anti-receptor antibodies, followed by anti-PY blot (A). The levels of the receptors 
were analyzed in total cell lysates with the respective anti-receptor antibodies (B) GAPDH was used as a loading control. C. Knockdown 
of HER2 in ovarian cell lines. Cells were infected with control vector (pLKO) and viruses including two different short hairpin sequences 
targeting HER2. Cell extracts were obtained and the receptor expression was measured by immunoprecipitation followed by Western blot 
with the anti-HER2 antibody. D. HER2 knockdown effect on the proliferation of ovarian cancer cells. Cells were infected with the indicated 
shRNAs. After selection, cells were then plated and counted after 5 days. Results are plotted as the mean ± s.d. of triplicates with respect 
to the proliferation of untreated cultures.
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Figure 3: Antitumoral action of T-DM1. A. Effect of different drugs targeting HER2 on the proliferation of four ovarian cancer cell 
lines. Cells were treated with 1 μM lapatinib and 50 nM of the rest of the indicated drugs for 7 days. Cells were counted and results plotted 
as mean ± s.d. of triplicates with respect to the proliferation of untreated cultures. B. Dose-response studies of the effects of T-DM1 on 
the four ovarian cancer cell lines. Cells were counted and results plotted as mean ± s.d. of triplicates with respect to the proliferation of 
control untreated cultures. C. Tumor sizes of control mice (n = 5) and those treated with trastuzumab and T-DM1 (n = 5 per group) with 
the schedules and doses indicated under ‘Materials and methods’. Data represent the mean ± s.d. Statistical analyses were performed on 
the measurements obtained at the end of the experiment (day 28), with the following results: Control vs trastuzumab, P = 0.504; Control 
vs T-DM1, P = 0.0001; trastuzumab vs T-DM1, P = 0.004. P values were calculated using Student t test (two-sided). D. Absence of 
relapse for large and small tumors after regression caused by T-DM1 treatment. The data plotted correspond to the measurements of two 
different tumors from two different animals which were followed for up to 72 days from the start of the treatment (65 days after the last 
T-DM1 injection). E. Effect of the combination of T-DM1 with chemotherapeutic agents used in ovarian cancer (carboplatin, cisplatin, 
docetaxel and vinorelbine). SKOV3 cells were treated with the indicated doses of the drugs and their MTT metabolization were measured. 
Combination indexes for the different drug combinations were obtained using the CalcuSyn program and plotted.
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levels of pHER2 were observed in the tumors of mice 
treated with trastuzamab when compated to untreated 
or T-DM1-treated mice. Together, these data indicated 
that T-DM1 exerted an important antitumoral effect on 
ovarian cancer cells which clearly outweighd the effect 
of trastuzumab.
Most antitumoral treatments are based on drug 
combinations which have clearly demonstrated superior 
antitumoral activities as compared to single treatments. 
Because of this, whether T-DM1 potentiated the action of 
chemotherapeutical drugs used in the ovarian cancer clinic 
was investigated. To this end, combinations of T-DM1 
with cisplatin, carboplatin, docetaxel or vinorelbine were 
tested in the SKOV3 and A2780 cells and the results 
analyzed by the Chou-Talalay algorithm [21]. Synergistic 
effects of T-DM1 with docetaxel and vinorelbine were 
observed (Figure 3E and Supplementary Figure 2).
T-DM1 arrests ovarian cancer cells in mitosis
The decrease in cell number caused by T-DM1 
could be due to inhibition of proliferation, stimulation 
of cell death or both. To investigate the mechanism of 
the antiproliferative effect of T-DM1 on ovarian cancer, 
SKOV3 cells were stained with propidium iodide and 
analyzed cytometrically at different times after addition 
of the drug. Treatment with T-DM1 caused accumulation 
of the cells in the G2/M phase of the cell cycle 
(Figure 4A and 4B). This effect was clear at 24 hours of 
treatment. At later times, although also evident, such effect 
was more difficult to appreciate due to the action of the 
drug on the cell cycle profiles.
To study whether T-DM1 arrested cells in G2 or M 
in SKOV3 cells, biochemical analyses of proteins whose 
levels mark different cell cycle phases were performed. 
To this end, SKOV3 cells were treated with T-DM1 for 
different times and cell lysates prepared to analyze the 
status of those marker proteins. Treatment with T-DM1 
caused accumulation of the mitotic markers pHistone H3 
and phosphorylated BUBR1, reaching a peak at 24 hours 
of treatment (Figure 4C). In addition, at 24 hours of 
treatment with T-DM1 dephosphorylation of CDK1 and 
a decrease in wee1, both events required for entry of cells 
in mitosis, were detected [22]. In addition, an increase of 
cyclin B, which acts partnering with CDK1 to allow entry 
of cells in mitosis and progression along prophase and 
metaphase, was also observed. Interestingly, an increase 
in the levels of p27 was also observed.
T-DM1 causes mitotic catastrophe of  
ovarian cancer cells
Morphologically, T-DM1 caused progressive cell 
rounding in cultures of SKOV3 cells, consistent with 
accumulation of cells in mitosis (Figure 5A and 5B). 
This accumulation of cells with a mitotic shape reached 
a peak at 24 hours decreasing thereafter (Figure 5B). 
Immunofluorescence analyses showed that T-DM1 caused 
appearance of aberrant mitotic spindles as soon as 6 hours 
after addition of the drug (Figure 5C).
Immunofluorescence analyses also demonstrated 
the appearance of giant multinucleated cells at longer 
incubation times (48 and 72 hours) with T-DM1 (Figure 5B 
and 6A). The rise in the appearance of these multinucleated 
cells followed an inverse time-course with respect to the 
mitotic cells, i.e. the progressive decrease in mitotic cells 
after 24 hours was followed by a concomitant progressive 
appearance of multinucleated cells (Figure 5B).
The presence of these multinucleated cells, likely 
caused by deficient spindle assembly due to the maytansine 
derivative, was indicative of mitotic catastrophe, a form 
of cell death triggered by deficient mitotic progression 
[23, 24]. Annexin V/propidium iodide staining experiments 
indicated that T-DM1 was unable to substantially increase 
apoptotic cell death at early (<24 hours) incubation times 
(Figure 6B and 6C). However, extension of the incubation 
with the drug for up to 10 days provoked a progressive 
increase in cell death (Figure 6C).
Treatment with T-DM1 caused a progressive 
derangement in the mitochondrial membrane potential 
(Figure 6D), indicative of increased permeability of 
the mitochondrial outer membrane, a process which is 
linked to cell death [25]. Increases in mitochondrial outer 
membrane permeability allow the release of cell death 
mediators from the mitochondrial intermembrane space, 
which may cause activation of executioner caspases, 
important mediators of cell death processes [25]. 
Treatment of SKOV3 cells with T-DM1 caused increase in 
cleaved caspase 3, which represents the active form of this 
caspase (Figure 6E). These increases in cleaved caspase 3 
were observed at 48 and 72 hours of treatment with the 
drug, times at which loss in mitochondrial membrane 
potential was already evident (Figure 6D). Together, these 
data indicate that treatment of SKOV3 cells with T-DM1 
caused cell cycle arrest which is temporally followed by 
progression into cell death.
DISCUSSION
The dismal prognosis of ovarian cancer in the 
metastatic setting has driven much research with the aim 
of developing therapeutic strategies to improve disease 
outcome [2]. Given the relevance of tyrosine kinases 
in cancer initiation/progression and the benefits of their 
targeting in other oncological diseases [26], we evaluated 
the activation status of several tyrosine kinases in tumor 
samples surgically resected from patients with ovarian 
cancer.
Antibody array analyses of the ovarian tumoral 
samples indicated that a large proportion of these tumors 
expressed activated forms of HER receptors, particularly 
HER2. Overexpression of HER2 has been reported in 
<10% of ovarian tumors [1], while in our active kinase 
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Figure 4: Effect of T-DM1 on the cell cycle of SKOV3 cells. Cells were treated with 50 nM T-DM1 for the indicated times and 
cell-cycle phases were quantitatively analyzed by PI staining and FACS. A. Cell cycle profile. B. Histograms representing the percentage 
of cells in the different phases of the cell cycle. C. SKOV3 cells were treated with T-DM1 (50 nM) and lysed at the indicated times. The 
expression of different proteins was determined by Western blot. GAPDH was used as loading controls. Bar graph quantitative analysis of 
the intensity of the bands with respect to GAPDH is shown.
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Figure 5: Mitotic arrest caused by T-DM1 in SKOV3 cells. A. Effect of T-DM1 on the morphology of SKOV3 cells grown as 
monolayers. 1.5 × 105 cells were plated in 35-mm dishes, allowed to adhere for 24 hours, then T-DM1 (50 nM) was added. The images were 
taken at the indicated points at x10 magnification. Scale bar = 40 μm. B. Percentage of cells with mitotic shape and giant multinucleated 
cells (GMC) in SKOV3 monolayers. Cells were treated with 50 nM T-DM1 and stained with DAPI and β-tubulin at the indicated points. 
GMC were defined as cells with at least three nuclei. Cells with mitotic shape and GMC were counted on a minimum of 10 randomly 
selected fields at x63 magnification. Data represent the average of positive cells (percentage) ± s.d./field. C. Effect of T-DM1 on spindle 
assembly and organization. SKOV3 were seeded on coverslips and treated with T-DM1 (50 nM) for 6 hours. Cells were fixed and stained 
for β-tubulin (green) and DNA (blue). Scale bar = 7,5 μm.
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Figure 6: T-DM1 provokes multinucleation and mitotic catastrophe in SKOV3 cells. A. Detection of giant multinucleated 
cells after T-DM1 treatment. SKOV3 were seeded on coverslips and treated with 50 nM T-DM1 for 72 hours. Cells were fixed and stained 
for nucleoporin p62 (red), actin (green) and DNA (blue). Scale bar = 25 μm. B. Effect of T-DM1 on Annexin V/PI staning of cells treated for 
24 hours with the drug. SKOV3 were treated with 50 nM for the indicated times, double stained with Annexin V-FITC/PI and analyzed by 
flow cytometry. C. Effect of T-DM1 on cell viability. The bar graph represents the percentage of viable (Annexin V-negative/PI-negative) 
and non-viable cells. D. Effect of T-DM1 on the mitochondrial membrane potential of SKOV3 cells. Cells were cultured and treated as 
above, harvested and stained to assess their membrane potential as described under the Materials and Methods section. E. Action of T-DM1 
on caspase 3. SKOV3 were treated with 50 nM T-DM1, lysed at indicated points and immunoblot analysis was done for caspase-3 or 
cleaved caspase-3.
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arrays the level of HER2 tyrosine phosphorylation was 
much higher (>90%). This observation indicated that 
the number of tumors in which HER2 was active may 
be higher than expected from the expression studies. 
Moreover, if HER2 is important in the pathophysiology 
of these tumors, then a substantial proportion of ovarian 
cancer patients could benefit from the targeting of HER2. 
Because of this, studies aimed at defining the biological 
relevance of HER2 in ovarian cancer were performed 
using model cell lines bearing different complements 
of HER2 receptors. In all the cell lines analyzed, HER2 
and its phosphorylated form were detected, although at 
different levels. Genetic studies using shRNAs targeting 
HER2 showed that in SKOV3 and OVCAR8 cells, 
knockdown of HER2 resulted in substantial growth 
inhibition. In contrast, in A2780 and IGROV1, HER2 
knockdown did not substantially affect their proliferation. 
These differences in the sensitivity to HER2 knockdown 
suggest that certain cell lines (SKOV3 and OVCAR8) may 
depend on HER2 signaling for proliferation. In contrast, 
even though A2780 and IGROV1 cell lines expressed 
HER2, signaling by this receptor does not appear to 
significantly contribute to their proliferation. These results 
raise the question of why lapatinib affected proliferation 
of IGROV1 while HER2 knockdown did not. This effect 
of lapatinib on IGROV1 cells may be explained by an 
off-target action of the drug, as has already been reported 
in other systems [27].
Several relevant considerations from the therapeutic 
point of view have to be made with respect to the HER2 
knockdown experiments. SKOV3 could be considered 
a model of ovarian tumors overexpressing HER2 
which could be suitable for therapeutic intervention by 
adequately targeting this receptor. In addition to HER2 
overexpression, other factors may contribute to HER2 
dependency in ovarian cancer. In this respect, it is 
interesting that targeting the neuregulins, a set of ligands 
which activate HER receptors [28], impedes proliferation 
of ovarian carcinoma cells [16].
The in vitro analyses of the effect of several 
approved anti-HER2 agents on ovarian cancer cell lines 
showed limited efficacy of trastuzumab or pertuzumab, 
in line with a previously published in vivo study [15]. 
In contrast, the trastuzumab derivative T-DM1 showed 
strong antitumoral properties both in vitro and in vivo 
on ovarian cancer cells. Because of this, we undertook 
a comprehensive study to characterize the molecular 
response of ovarian cancer cells to T-DM1. Dose-response 
curves indicated that the most sensitive cell line was 
SKOV3. This may be explained by the concurrence 
of two situations: the high expression level of HER2 
and the addiction to HER2 observed in SKOV3 cells. 
Mechanistically, T-DM1 provoked cell cycle blockade 
in mitosis, as indicated by the accumulation of cells in 
this phase of the cell cycle and the increased amounts of 
proteins such as pHistone H3 and pBUBR1, which mark 
this phase of the cell cycle. The accumulation of cells in 
mitosis could be caused by the maytansinoid derivative 
which was likely responsible for the disruption of normal 
spindle assembly observed in cells treated with T-DM1. 
This caused augmented numbers of mitotic cells in the 
cultures, which then evolved into multinucleated cells. 
While the direct effect of the antiproliferative action 
of T-DM1 appears to be on the cell cycle dynamics, 
prolonged treatment with the drug caused cell death. Such 
phenomenon may be secondary to the mitotic arrest of 
cells and multinucleation, which characteristically lead 
to mitotic catastrophe, which has also been reported in 
breast cancer [24]. Interestingly, T-DM1 synergized with 
docetaxel and vinorelbine. It is therefore possible that 
drugs altering microtubule dynamics may augment the 
antitumoral action of T-DM1. In addition, T-DM1 caused 
an increase in the levels of p27. This effect may be due to 
the trastuzumab part of the compound, as this antibody 
has been formerly shown to provoke this biochemical 
effect [29]. This increase in p27 has been linked to delayed 
transit of the cells from G1 into S. While this effect may 
contribute to the composite antitumoral effect of T-DM1 
it is clear that the mitotic arrest effect predominates over 
other effects of the drug on the cell cycle.
Of note, T-DM1 was effective not only in the cell 
lines that were sensitive to in vitro knockdown of HER2, 
but also in cell lines resistant to such knockdown. Thus, it 
is possible that in cells which are not addicted to HER2, 
the low levels of HER2 could act favoring the entry of 
T-DM1 into the cell. Alternatively, an effect of T-DM1 in 
these cell lines caused by constitutive internalization of 
extracellular milieu products could also be responsible for 
the antiproliferative action of T-DM1. In fact, we observed 
internalization of T-DM1 in all the cell lines analyzed 
(Supplementary Figure 3). The fact that tumoral cells are 
characterized by a high proliferation rate may then explain 
the antitumoral effect of T-DM1 on these HER2 low and 
knockdown-resistant cells. Moreover, pharmacokinetic 
studies [30] have reported plasma concentrations of 
T-DM1 above the maximal doses tested in our study 
and sustained for up to 20 days. This is important, as it 
is possible that ovarian patients with tumors bearing low 
levels of HER2 may also benefit from the antitumoral 
properties of T-DM1.
In summary, the work herewith reported describes 
the activation status of several druggable tyrosine kinases 
in ovarian cancer. The study reports frequent activation 
of HER2 in the tumoral samples and shows preclinical 
evidence that acting on HER2 exerts an antitumoral action 
on cells expressing this protein. Because of the much better 
effect of the trastuzumab derivative T-DM1 with respect to 
other clinically available drugs and its potentiation of the 
effect on classical standard of care drugs, the preclinical 
data presented here call for the clinical evaluation of 
T-DM1, either alone or in combination, for the therapy of 
ovarian cancer.
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MATERIALS AND METHODS
Reagents and antibodies
Cell culture media, puromycin, MTT and DAPI were 
purchased from Sigma-Aldrich (St Louis, MO, USA). 
Fetal bovine serum (FBS) and penicillin/streptomycin 
were from Invitrogen (Gaithersburg, MD, USA). Protein 
A-Sepharose was from GE Healthcare Life Sciences 
(Piscataway, NJ, USA). Carboplatin and cisplatin were 
from Pfizer (Madrid, Spain). Docetaxel was from Hospira 
UK Ltd (Warwickshire, United Kingdom). Vinorelbine 
was from Pierre Fabre (Barcelona, Spain). Lapatinib was 
from LC Laboratories (Woburn, MA, USA). Trastuzumab-
emtansine (T-DM1) was purchased from a pharmacy 
located in Andorra. Trastuzumab was purchased from 
a local pharmacy and pertuzumab was obtained from 
Genentech (San Francisco, CA). Other generic chemicals 
were purchased from Sigma, Roche Biochemicals or 
Merck (Darmstadt, Germany).
The antibodies against Abl, CSF-1R, EphA2, FAK, 
FGFR1, FGFR2, FGFR3, FGFR4, Flt3, IGF-1R, Met, 
PDGFRα, PDGFRβ, Ret1, Ret2, Src, pY99-HRP, cyclin 
B, cyclin E, Wee1, p27, CDK2, CDK4 and GAPDH 
were purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA). The anti-pH3, anti-p(Y15) CDK1, anti-
pRpb1, anti-pRb (S780) and anti-pRb (S807/811), pHER2 
(Y1221/1222), pHER3 (Y1289), and AKT antibodies were from 
Cell Signaling Technologies (Beverly, MA, USA). The 
anti-c-Kit, anti-cyclin A, anti-cyclin D3, anti-BUBR1, 
anti-caspase 3, anti-cleaved caspase 3 anti-pAKT (S473) 
and anti-Nucleoporin p62 antibodies were from BD 
Biosciences. The anti-Dtk, anti-VEGFR1, anti-VEGFR2 
and VEGFR3 antibodies were from, R&D Systems 
(Minneapolis, MN, USA). The anti-β-tubulin antibody was 
from Sigma-Aldrich. The rabbit polyclonal anti-calnexin 
antibody was from Stressgen Biotechnologies Corporation 
(British Columbia, Canada). Horseradish peroxidase 
conjugates of anti-rabbit and anti-mouse immunoglobulin 
G were from Bio-Rad Laboratories (Hercules, CA, USA). 
The 4D5 anti-HER2 antibody was provided by Dr. Mark 
X. Sliwkowski (Genentech, San Francisco, CA, USA). 
The Ab-3 anti-HER2 antibody used for Western blotting 
was from Calbiochem (La Jolla, CA, USA). The anti-
EGFR, anti-HER3 and anti-HER4 antibodies have been 
described previously [31].
Cell culture and infection with lentivirus
All cell lines were cultured at 37°C in a humidified 
atmosphere in the presence of 5% CO2 and 95% air. The 
cell lines were provided by Dr. Faustino Mollinedo (CSIC 
Salamanca, Salamanca, Spain), who obtained them from 
the American Type Culture Collection. No authentication 
was conducted in the author’s laboratory. OVCAR8 and 
SKOV3 cells were grown in Dulbecco’s Modified Eagle’s 
Medium (DMEM) and A2780 and IGROV1 in RPMI-1640 
medium containing a high glucose concentration 
(4,500 mg/L) and antibiotics (penicillin at 100 mU/mL, 
streptomycin at 100 μg/mL) and supplemented with 10% 
FBS.
Knockdown of HER2 in ovarian cells was performed 
by infection with lentiviral particles. The lentiviral 
vectors containing short hairpin RNA (shRNA) for HER2 
were obtained from Thermo Scientific (Waltham, MA, 
USA). A minimum of 5 different shRNA sequences were 
tested and the two that produced higher knockdown levels 
were used for the proliferation experiments. Preparation of 
lentiviral vectors was performed as described previously [32].
Patient samples and antibody arrays
Tyrosine phosphorylation of different tyrosine 
kinases was evaluated by antibody arrays in ovarian 
cancer samples from patients of the University Hospital of 
Salamanca. Fresh tissue samples from the primary tumors 
were embedded in OCT (Fisher Scientific) and then in 
isopentane, and placed at -80°C. Selection of the tumoral 
tissue was performed after excision of part of the tumor 
and staining with hematoxylin/eosin. The tumors were 
minced, washed with PBS and homogenized (Dispomix, 
L&M Biotech, Holly Springs, NC, USA) in ice-cold lysis 
buffer (1.5 ml/100 mg of tumour). This homogenate was 
centrifuged at 10,000 xg for 20 minutes at 4°C and the 
supernatants were transferred to new tubes.
To perform the antibody arrays, each antibody 
(0.1 μg) in duplicate was spotted onto a nitrocellulose 
membrane. The membrane was dried at room temperature 
for 30 minutes and then blocked for 2 hours in 
Tris-buffered saline with Tween (TBST) containing 5% 
bovine serum albumin (BSA). The membranes were 
then incubated with 1 mg of protein lysates overnight 
at 4°C. The membranes were washed in TBST three 
times during 10 minutes and incubated for 2 hours 
with the anti–phosphotyrosine-HRP antibody (1:5,000 
dilution). After three washes of 10 minutes each in TBST, 
membranes were incubated with the ECL Plus Western 
Blotting Detection System (GE Lifesciences). Breast 
cancer cell lysates from BT474 cells were used as the 
positive control, as they contain high levels of resting 
tyrosine phosphorylation of several cellular proteins [33]. 
Control Ig and PBS were spotted as negative controls. 
Quantification of the different spots in the array was 
performed using the Image Studio Digits V3.1 Odyssey 
program (LI-COR, Lincoln, NE, USA).
Immunoprecipitation and western blotting
Cultured cells were washed with phosphate-
buffered saline (PBS) (NaCl, 137 mM; KCl, 2.7 mM; 
Na2HPO4, 8 mM; KH2PO4, 1.5 mM) and lysed in 
ice-cold lysis buffer (20 mM Tris–HCl [pH 7.0]; NaCl, 
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140 mM, EDTA; 50 mM; 10% glycerol; 1% Nonidet 
P-40; 1 μM pepstatin; 1 μg/mL aprotinin; 1 μg/mL 
leupeptin; 1 mM phenylmethyl sulfonyl fluoride; 1 mM 
sodium orthovanadate). Lysates were centrifuged at 
10,000 xg at 4°C for 10 minutes and supernatants 
were transferred to new tubes with the corresponding 
antibody and protein A-Sepharose. Immunoprecipitations 
were performed at 4°C for at least 2 hours. Immune 
complexes were recovered by a short centrifugation 
at 10,000 xg for 15 seconds, followed by three washes 
with 1 mL cold lysis buffer. Samples were then boiled in 
electrophoresis sample buffer and placed on SDS-PAGE 
gels at varying acrylamide concentrations, depending 
on the molecular weight of the proteins to be analyzed. 
After electrophoresis, the separated proteins in the gel 
were transferred to polyvinylidene difluoride membranes 
(PVDF) (Millipore Corporation, Bedford, MA, USA). 
Membranes were blocked in TBST (100 mM Tris [pH 
7.5]; 150 mM NaCl; 0.05% Tween 20) containing 
1% BSA or 5% skimmed milk for 1–3 hours and then 
incubated with the corresponding antibody for 2–16 hours. 
After washing three times with TBST during 10 minutes, 
membranes were incubated with HRP-conjugated anti-
mouse or anti-rabbit secondary antibodies for 30 minutes. 
After the secondary antibody, the membranes were washed 
three times with TBST and the bands were visualized by 
using enhanced chemiluminescence [34].
Cell proliferation, cell cycle and apoptosis assays
Cell proliferation was assessed by MTT 
metabolization or cell counting. For the MTT assays, 
cells were seeded in 24-well plates and allowed to 
attach overnight in DMEM or RPMI-1640 + 10% FBS. 
The next day medium was replaced with complete 
medium containing the different drugs. After treatment, 
cell proliferation was analyzed by an MTT-based assay 
as previously described [35]. For the cell counting 
experiments, cells were seeded in 6-well plates and 
cultured as above. Once the treatment finished, cells were 
counted using a Z1 Coulter Particle Counter (Beckman 
Coulter, Pasadena, CA, USA). Unless otherwise indicated, 
the results are presented as the mean ± standard deviation 
of triplicates of a representative experiment.
To determine whether the combination of T-DM1 
with chemotherapeutic agents (carboplatin, cisplatin, 
docetaxel and vinorelbine) was synergistic, additive 
or antagonist, we used the CalcuSyn v2.0 software 
programme (Biosoft, Ferguson, MO, USA) [35]. This 
program allows the calculation of the combination index 
based on the algorithm of Chou and Talalay. Combination 
index values less than 1 indicate synergism, values equal 
to 1 indicate an additive effect, whereas values greater 
than 1 indicate antagonism.
For the analysis of the cell cycle profile, cells 
were treated with T-DM1 for the indicated period of 
time and subsequently collected by pooling together the 
nonattached and attached cells. After washing with PBS, 
cells were fixed and permeabilized by ice-cold 70% 
ethanol overnight. Cells were centrifuged, resuspended in 
500 μL of PBS containing 250 μg DNase-free RNAase A 
(Sigma-Aldrich) and incubated at room temperature for 
2 hours. Then, 2.5 μg of propidium iodide (PI; Sigma-
Aldrich) were added. DNA content and cell cycle analyses 
were performed by using a BD Accuri C6 flow cytometer 
and the C6 software (BD Biosciences).
For apoptotic analysis, cells were treated with 
T-DM1 for the indicated times and subsequently collected 
by pooling together the nonattached and attached cells. 
Then, cells were washed with PBS and resuspended in 
100 μL of binding buffer (10 mM HEPES/NaOH [pH 7.4]; 
140 mM NaCl; 2.5 mM CaCl2) containing 5 μL of Annexin 
V-fluorescein isothiocyanate (FITC; BD Biosciences) and 
5 μL of 50 μg/mL PI. Cells were incubated for 15 minutes 
in the dark. After adding another 400 μL of binding buffer, 
labeled cells were analyzed in a BD Accuri C6 flow 
cytometer. Analyses of mitochondrial membrane potential 
in ovarian cancer cell lines has been described [35].
Immunofluorescence microscopy
Cells cultured on glass coverslips were washed 
with PBS and fixed in 2% p-formaldehyde for 
30 minutes at room temperature, followed by a wash in 
PBS. Monolayers were quenched for 10 minutes with 
PBS with 50 nM NH4Cl2. Cells were then permeabilized 
for 10 minutes with PBS supplemented with 0.1% 
(final concentration) Triton X-100 and then blocked 
in PBS with 0.2% BSA for 10 minutes. Monolayers 
were incubated with the indicated primary antibodies 
in blocking solution for 1 hour at room temperature. 
After three washes for 10 minutes each in PBS with 
0.2% BSA, coverslips were incubated with Cy3- or 
Alexa 488-conjugated secondary antibodies or with a 
50 mg/ml FITC-labeled phalloidin (Sigma-Aldrich) 
solution in PBS with 0.2% BSA for 30 minutes at 
room temperature. After three washes for 10 minutes 
each in PBS with 0.2% BSA, immunolabeled cells 
were counterstained with DAPI to detect cell nuclei 
and the slides were mounted. Samples were analyzed 
by regular epifluorescence microscopy or by confocal 
immunofluorescence microscopy using a Zeiss LSM510 
system.
Xenograft studies
Mice were manipulated at the animal facility 
following legal guidelines. Female BALB/c nu/nu 
mice (7 weeks old) were obtained from Charles River 
Laboratories (Wilmington, MA, USA). A total of 5x106 
SKOV3 cells in 100 μl of DMEM and 100 μl of Matrigel 
(BD Biosciences) were injected subcutaneously into 
the right and left flank of each mouse. When tumours 
reached a mean volume of 200 mm3, animals (n = 15) 
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were randomized into three groups (with equal average 
tumour volumes) (vehicle (PBS) n = 5, trastuzumab n = 5, 
and T-DM1 n = 5). Mice were treated twice (day 0 and 
day 7) at the first week with trastuzumab (15 mg/kg) and 
T-DM1 (15 mg/kg) intravenously. Tumour diameters 
were serially measured with a calliper twice per week and 
tumour volumes were calculated by the following formula: 
volume = width2 × length/2. Mice treated with vehicle and 
trastuzumab were sacrificed on day 28. Mice treated with 
T-DM1 were maintained to assess whether their tumors 
relapsed.
Statistical analyses
Comparisons of continuous variables between two 
groups were performed using a two-sided Student’s t test. 
Differences were considered to be statistically significant 
when P values were less than 0.05. Statistical data are 
presented as the mean ± s.d. All data were analyzed using 
the statistical software SPSS 21.0 (SPSS Inc., Chicago, IL).
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